KalVista Pharmaceuticals (KALV) Change in Receivables (2025)

KalVista Pharmaceuticals (KALV) reported Change in Receivables of $1.9 million for Q3 2025.

KalVista Pharmaceuticals (KALV) Change in Receivables (2025) Analysis & Trends

KalVista Pharmaceuticals (KALV) has 1 years of Change in Receivables data on file, last reported at $1.9 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 75.30 Mn
4 NuCana 279.75 Bn 279.75 Bn - 2.84 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -39.80 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -1.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 KalVista Pharmaceuticals 1.36 Bn 1.36 Bn 49.41 Mn 1.93 Mn

Historic Data

Download Data
DateValue
Jul 31, 2025 1.93 Mn
Jul 31, 2025 1.93 Mn